CRT and Waypharm in thioplatin deal
Cancer Research Technology, a UK-based oncology-focused development and commercialization company, has entered into an agreement with French drug developer Waypharm SAS, under which the latter will evaluate the former's anticancer agent thioplatin. The drug is a novel hypoxia-responsive platinum-based cancer therapy, which was originally developed by researchers at the Deutches Krebsforschungszentrum (German Cancer Research Center) in Heidelberg.
Under the terms of the deal, CRT has granted Waypharm an exclusive six-month option to in-license worldwide development and commercialization rights to the drug in return for an upfront payment. CRT added that it has agreed licensing fees, development-related milestones and royalties following the successful commercialization of the agent.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze